The criticaJ role that androgens play in the etiology of acne has led to a search for topically acti ve antiandrogens and the frequent use of the flank organ of the golden Syrian hamster as an animal model. 17-a-propyltestosterone (17-PT) has been identified as ha ving potent 3ntiandrogen.ic activity in the hamster model , and this report describes its clinical evaluation. Two double-blind placebo controlled studies comparing 4% 17 -PT in 80% alcohol versus vehicle alone were conducted. One study examined 17-PT sebosuppressive act ivity in 20 subjects. The second study examined its effi cacy in 44 subj ects having mild to moderate acne. A third study F or many years now the critical role of androgens in the etiology of acne has been recognized 11] and th is has led to a search for phannacologic agents that selectively block the: action of androgens on the sebaceous gland.
The criticaJ role that androgens play in the etiology of acne has led to a search for topically acti ve antiandrogens and the frequent use of the flank organ of the golden Syrian hamster as an animal model. 17-a-propyltestosterone (17-PT) has been identified as ha ving potent 3ntiandrogen.ic activity in the hamster model , and this report describes its clinical evaluation. Two double-blind placebo controlled studies comparing 4% 17 -PT in 80% alcohol versus vehicle alone were conducted. One study examined 17-PT sebosuppressive act ivity in 20 subjects. The second study examined its effi cacy in 44 subj ects having mild to moderate acne. A third study F or many years now the critical role of androgens in the etiology of acne has been recognized 11] and th is has led to a search for phannacologic agents that selectively block the: action of androgens on the sebaceous gland.
Inasmuch as the systemic use of antiandrogens is likel y to be accompanied by signifi cant adverse reacrions second.u-y to effects on oth er androgen sensitive structures . the search fo r effi cacious topical agents has become th e more ranonal approach.
Following a systematic sc re~nin g of androstane and androstene analogues of testosterone, Ferrari et al [2J reported on the discovery of a compound, 17-a -propyl testosterone (17-PT). which effectively suppressed androgen-induced enlargeme nt of the sebaceous gland in two animal models. the flank organ of the Syrian hamster and the supracaudal gland of the guinea pig. T opical appliation of thi s compound to mature male hamsters induced a reve rsible regression of the fl an k organ in ;a dose-de~l1de.nt f;ashion with no evidence of systemic acti vity. Th e effect was seen w ith doses ranging from 10-250 /lg/ day, incorporated in S /ll ethanol and directly applied to t he skin overl ying th e fl ank o rgan. The mechanism of action of this dru g is thought to be direct blockade of dihydrotestosterone bind ing to tissue receptors [3] .
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• N/ C: nodules/ cysts Pap: papule Pust: pustule Ro 15-0778: {E)-l ,2,3,4,-tetrahydro-I,1 ,4.4,-tea:unethyl-6-(1 -methyl-2-phenylethenyl)naphthalene SER: sebum excretion rate 17-PT: 17-a-propyhestosterone measured in vitro percutaneous absorption of 17 -PT through hamster flank and monkey skin, and human face skin in-vivo, using radioactive drug. 17-PT was found to be ineffective in reducing either the sebum excretion rate or the number of inflammatory acne lesions. Failure of 17-PT to show clinical activi ry was not a result of poor percutaneous absorption. T otal abso rption in man was 7.7% of the dose and only 1.0% in the hamster. The sebaceous gland ofhamSler flank organ is apparendy more sensitive to antiandrogens than the human sebaceous gland.) Illvest DermatoI93: 475 -479, 1989 Al though 17-PT was later clinicall y eval uated in the treatment of acne , it was found to be with om efficacy in man, and the resuJrs were never published. Recently, preliminary publication [4, 5] of da ta on a seco nd drug (Ro 15-0778), which was found to suppress the sebaceous gland in animal models but was without effect in man , has been noted. This has prompted us {Q repo" the data originall y obtained on 17-PT and to question the continued we of the hamster fl ank organ model for the study of the human sebaceow gland.
The data presented here arc derived from t hree separate studies. The percutaneous abso rption of 17-PT has been eval uated in a series of in vitro and in vivo studi es. and clinical evaluations ofboch sebum suppression and efficacy in acne have been conducted in human volun teers.
MATERIALS AND METH ODS
17-PT (17-a-propylandrost-4·en-I7p-ol-3-one, W IN 17,665) was supplied by Sterl ing-W inthrop Research l nstitute (Rensselaer, NY) (Fig I) .
Th e formulation used in all studies involving topical appl ication of the drug was 4% (w/ v) 17-PT in a vehicle consisting of 80/ 20 e-th:molfwater. For the acne and sebum suppression studies the formulatinn was suppl ied as saturated fiber pads, packaged 42 per jar. For the percutaneous absorption an.d bioavailability studies, carbon141abcJed 17-PT, specific activity of3.7 /lei/ mmole. was incorporated into th e standard stock formul ation in tr2cer amounts. The one exception involved subcutaneow injection in the monkey, where only radioactive drug was used ( 0 take advantage: of a higher specific activiry. In this case a 1.2% solutio n of drug in 95% ethanol was used.
Approval to cond uct the: in vivo studies was obt2l.ned from the appropriate Human Subjects Investigational Review Boards. Written infonned consent was o btained from 211 subjects including parent2l consent where necessary. HtlttlSU!r: Six mature male Syrian hamsters (Charles River laboratories) were killed by Nembutal injection and the hair on th e back c10sd y shaved with electric clippers. Duplicate full -thickness specimens from both flank organ-conuining skin and non-flank organ skin were (:I .. ken from each animal and mounted on diffusion cells in which 1.0 crn 2 of skin surface was available for study. Following a I-h equilibration period, 10 p:l of radioactive test solution was appl ied to the epidermal surface. and absorption was assessed by removing th e dermal bathing solution in toto at regular intervals and anal yz in g for radioactive content.
Mot/key: Back skin from three monkeys (Macaca nemcsrrina) was obtained through the Unive.rsity o f W as hington Regional Primate Center Tissue Program. Skin was prepared. mounted onto diffusion chambers, and percutaneous absorprion of 17-PT was performed as desc ribed above.
Subcutaneous injection of 17-PT was also perfonned in the rh esus mon key in order to determ ine fractional urinary excretion , a factor needed for the calculation of total absorption following top, ical appl ication in man (see below). Three adult rhesus monkeys (Macaea mulatta) were tranquilized wi th Ketamine; a portion of their backs was shaved with cleerric cl ippers; and the animals were placed in metabolism chairs (Plas-Labs. Lansing, MI). iUdioacnve t 7-PT, approximately 10,uCi in 0.075 ml ethanol, was injected into the subcuuneow space of [h e back wing a microsyrin ge. T ota.! urinary ourput was collected for 5 d and analyzed for radioactive content to determine the fractional dose excreted in the urine.
Huma'l: Human abdominal skin was obtai ned ar autopsy from three adul t donors, moumed on diffusion chambers, and pe rcutaneous absorption of 17-PT was performed as previously described.
Th.e in vivo percutaneous absorption of 17-PT was evaluated in five healthy young adult male subjects. The subjects were prohibited from using topical medications for I week prior to the start of th e study. None of the subjects had used topical or systemic rerinoids . .
On the morning of the first study day . 15 min pdor to dosin%, control urine specimens were collected from each subject and a mild soap (Alpha-Ken.) and water wash of the face comp leted. T hen 0.1 mJ of radioactive test solution was app lied by micropipette to 50 cm 2 face skin, eq ually divided berween cheek and forehead, and evenly spread with a gtass rod. . . The subjects were allowed to go about th eir normal daily activities but were instructed not to rub or wash their faces and to avoid activities that would stimulate sweating. Radioactive drug remained on the face for 10 h, then was washed off with soap and water.
THE J OURNAL OF INVESTIGATIVE DeRMATOLOGY
Tora! urinary output was collected fo r 5 d at 2.S-h intervals for the first 10 h and at approximatel y 12·h intervals thereafter. Five milliliters of each urine specimen was gelled with 10 ml scintillation fluid (Aquasol-lI) a.nd counted in a liquid scintillation spectrome.ter. Que.nching was corrected by the external standard method. Parricularly dark urine speci mens were fint diluted with diS[iJled water prior to sampljng.
Ten-milliliter blood samples were obtained at the same time points as urine collections were made and serum was separ,tted. Duplicate O.5-ml aliquots of serum were taken and each added to 4.5 ml water, gelled with 10 011 scintillation fluid, and coumed.
Tot'al percuran eous absorprion of 17-PT was calculated from the summarion of all radioactivity found in the urine and the use of a correction factor to adjust for radioactivity excreted vi.a other routes. The correction fdetor, i.e .. the fraction of a systemically administered dos~ co be excreted in the urine. was determined in the experimenu in which radioactive 17-PT was injected subcutaneously in the monkey as described previously.
Acne Efficacy and Sebum Suppression Studies The efficacy of 17-PT in the treatment of acne was assessed in a placebo-controll ed. double-blind study. Forty-four male subjects, ages 14 -20, having mild [ 0 moderate facial acne and a minimum lesion count of 10 papules/pustules. were recruited and randoml y assigned to ei ther active or placebo treatment. For each subject a history was taken and physica l exa mination and screening laboratory evaluations were done prior CO [h e start of rhe study. No form of acne therapy other than the te"st medication was allowed during th e study. and subjects had to be off all systemic antibiotics for 1 month and all topical medications for 2 weeks prior to initiation of tht' test therapy.
Th e-study ran for 12 week s with rh e test medication being applied three times dail y. Subjects werC instructed ro make the morning and evening applicati ons following a face wash. Efficacy was evaluated by lesion count, and the subjects were see n at O. 2, 4, 6. 8, and 12 weeks. At each visit all inflammatory lesions on th e en tire face were counted and recorded. In addition. the oilin ess of four sites (chin, cheek s. nose, and fo rehead) were graded individually by inspection using a 0-3 scale. where 0 represented no oil and 3 represe nted extreme oiliness. For purposes of statisncal analysis the grades for the four sites were summed. Signs of irritation were also nored. At the end of the study the code was broken and S[atistical evaluation of the r~ults made.
The ability of 17 -PT to red uce the rate of sebum excretion was evaluated in a separate double-blind, placebo-controlled srudy in 20 health y males, 22-3 1 yea rs of age, having mild to moderate acne. Each was given a physical exami n . .
:aion, incl uding screening laboratory eval uation to insure that rhey were in good healt h, then randomly assigned to ei cher active or placebo treatment. All topical therapy must have been discontinued at least 1 wt"ek prior to entry into the study.
The study was divided into two phases: a 3-week control period during which onl y placebo pads were used by all subjects. and a 9-week treatment period during which those assigned to active therapy rece ived drug-conta inin g pads. Application was three times daily for all subjects during both phases. During the 3-week control period. weekl y evaluation of the sebum excretion rate (SER) of forehead skin and plasma testos terone was made for the purpose of establishing baseline values. During the treatment phase these parameters were measured ar 4, 6. 8, and 9 weeks.
The SER was determined gravimetrically following a 3-h collection period using a previously published technique (71, and plasma testosrctO, nc was determined by radioimmunoassay.
RESULTS
Data obtained on the percutaneous absorption of 17-PT in the hamster, monkey. and man are p resented in Table I . 17-PT absorption is generally found to be low, except for human face skin. irrespective of the species examined. Skin overlying the flank organ of the hamster is no more permeable than that of adjacem non-gland skin or that of monkey skin. In fac t, skin overlying the Aank organ is statistically less permeable: (p=O.OS) chan that of adjacent skin (1.0% versus 2.3% of the applied dose). 17-PT absorptio n through human abdominal skin (0.4%) is even lower than either hamster (1-2.3%) or monkey skin (1.4%). However, 17-PT absorption through (ace skin is conside rably higher (7.7% of the app lied dose). T he rate of urinary excretion of radioactivity following application to the (ace of five volunteers is show n ill A sum mary of th e results obtained in the acne clinical study is givcn in Table n . As there were no clinically significam differences secn berween the placebo and active formuladons at any of the intermediate grading periods, only the data from the baseline and final grading periods arc presented. It can be seell that, with one exception, there are no differences berween active and placebo treatment at week 12 in the parameters papules, pustules, or oi liness. With respect to papules and pustules, not even a placebo effect is noted in this study, i.e., there is no improvement from week 0 ro J 2. A non-significant trend toward improvement in the oiliness score with time is seen for both active and placebo trcatmem. This effect is probably attributable to the physicaJ removal of surface oil secondary to t.i.d . use of the ethmol saturated pads.
The single paramNer in which a sta[istically significant difference berween active and placebo trearment is seen ar week 12 is wirh nodules/ cysts (N / C). In view of th e facr that the study was not designed to primarily examine nodulo-cystic acne and tbe-number of lesions in the N /C category are very small, the difference between treatments is felr to be a chance occurrence onJy. In keeping with rhis concl usion it should be noted that rhe difference bern'een week 0 and week 12 in the N /C count is nor statistical ly signincant for eirher active or placebo therapy. The effect of 17~PT on th e SER is shown in Table III . Nineteen of che twemy test subjects successfully completed the entire course of therap}'. One subject was dropped after failing to return for three of the four eval uation visits. N o statistically signi6cam differe.nces were observed at any time point between active and placebo therapy , nor were any significant differences observed between the control {mean} and treatment period [or I:ither active or placebo therapy. Two subjects in rhe-placebo group experienced some transie.nt facial irritarion during th" cou rse of the stud y. H owever, both were able to continue in the stud y, and the reactions disappeared without th e need for rreatme.nt.
The effect of 17-PT on plasma testosterone levels of the same ninctcen subjects is presented in Table IV . There were no statistically signifi cant differences becween aCtive and placebo therapy at an y time point nor were there any signilicam differences between the control (mean) and treatment period for either active or placebo therapy .
DISCUSSION
Th e ~ank organs (costoverrebr.al glands) of the golden Syrian hamster are widely used as a model for the human sebaceous gla nd (8) .
They are gross ly vlsible paired structureS, situated on the back of r.h e animal , and co main sebaceous g lands, large pigmented hair follicles, and dermal me1anocytes. The utility of the flank organ to the dennatopharmacologist derives from rhe fact that all three of its componen ts are androgen sensirive, alrhough most work fO date has focused on the sebaceous glands. In the mature male hamster tbe sebaceous glands are palpable , 6 -8 mm in diameter, and almost fill the entirety of the dermis. In immature males, castrated m:tles, and mature femal es, the g lands are much sma ller but can be stimulated to full porential by topical or parenteral administration of testosterone or other androgens .
This response to androgen adm.inistration has become the basis of the model and has allowed invc:stigators {O sysrematically screen drugs fo r their ability to block the stimulatory effect of androgens, i.e .. to screen fo r antiandrogeru. The model can be further refined with respect ro tOpically applied anriandrogens in that local -versussystemic activity can be deduced. Unilateral administration of a systemicall y active drug will lead to an effect on both. glands, Trcatmenr Period (week) Th e data obtained in the present study offer further proof that the hamster flank organ model fails to accurately predict therapeuti c efficacy in man. Though active topically in the hamster at doses ranging from 10 -250 Jig/day (equivalent to s.olutions ranging from 0.2 -5.0% in concentration), in man a 4.0% sol ution of 17-PT was found to be ineffective in the treatment of acne as well 3..,; in the inhibiti on of SER. Given the known differences in percutaneous abso rption between the skin of animals and man, ir seemed likel y that rhe therapeutic failure observed in the present study might well be due to low drug permeation in man. H owever, because direct measurement found human face skin to be more penncable than the skin overlying the flank organ (7.7% versus 1..0% of tbe dose, respectively), it is clear that differences in absorption cannot account for th e observed differences in pharmacologic activity. ThC' possibiliry of d ifferent skin metabolic profiles of 17-PT in hamster and man as an ex p!an~tion of the observed species differences cannot be rul ed o ut at chIs nme, Altho ugh the sin g le failure of the hamster fl ank organ modc::l reported here does nor j ustify condemnation of the modc::l , w h en coupl ed with the recentl y reponed experie nce on Ro 15 -0778 one must serio usly question th e relevance of th e model. 17-PT is an antiandrogen whose activity is dependent u pon bloc kade of the dihyd roteslosterone recepror. Ro 15-778 is a retino id whose mechanism of action is unclear, but which is known to be devoid of antiandrogen activity a nd, the re fore, is acting by a m echanism unrelated to that of 17-PT. Given that twO d rugs of unrelated structure and pharmacologic aCfiviry both fail in man, in spite o f unequi vocally good activity in th e fl ank o rgan and comparable topical bioavailabili ty, it is clear that the model has failed.
What is particula rly puzzling is the failure of the £lank o rgan m o del to accurately predict th e lack o f efficacy of Ro 15-0778, because prior work with re tinoids had shown good correlation between the model and clinical efficacy. In a study directly comparin g isorretinoin with th e aromatic retinoid er retinate , both dosed by subcutaneous injection, Gomez [17] found that isorretinoin significantly suppressed tbe flank o rgan, wh ereas e trerinatc w as virtuall y without e!lect. These results parallel th e clinical observations of Goldstein et al [18J. in which erret illate w as found to be muc h less efficacious than isorretinoin in the treatment of nodulo-cystic acne. The reduction in SER and lesion count at [he end o f therapy (8 weeks) was 2 1% and 8% fo r etretinate, versus 86% and 43% for isotretinoin.
One explanation for rbe disparate results obtained with the aroronoid derivative Ro 15-0778 m ay be that this d ru g is not a typical retino id or. perhaps . not a rerinoid at all. In most bioassay systems used to screen rerinoids. this drug is inactive. W e do not suggest the abandonment of rhe Hank organ model. but rather a better understanding of its biochemical make up and pharmacologic response relative to the human sebaceous gland.
